ACADIA Pharmaceuticals In... (ACAD)
ACADIA Pharmaceuticals Statistics
Share Statistics
ACADIA Pharmaceuticals has 166.79M shares outstanding. The number of shares has increased by 0.95% in one year.
| Shares Outstanding | 166.79M |
| Shares Change (YoY) | 0.95% |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | 98.1% |
| Shares Floating | 165.49M |
| Failed to Deliver (FTD) Shares | 52 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 15.62M, so 9.36% of the outstanding shares have been sold short.
| Short Interest | 15.62M |
| Short % of Shares Out | 9.36% |
| Short % of Float | 12.63% |
| Short Ratio (days to cover) | 10.45 |
Valuation Ratios
The PE ratio is 13.43 and the forward PE ratio is 15.44. ACADIA Pharmaceuticals's PEG ratio is -0.03.
| PE Ratio | 13.43 |
| Forward PE | 15.44 |
| PS Ratio | 3.17 |
| Forward PS | 1.5 |
| PB Ratio | 4.15 |
| P/FCF Ratio | 19.34 |
| PEG Ratio | -0.03 |
Enterprise Valuation
ACADIA Pharmaceuticals has an Enterprise Value (EV) of 2.77B.
| EV / Sales | 2.9 |
| EV / EBITDA | 27.69 |
| EV / EBIT | 17.58 |
| EV / FCF | 17.64 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.38 |
| Quick Ratio | 2.32 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.52 |
| Debt / FCF | 0.33 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 30.9% and Return on Invested Capital is 25.22%.
| Return on Equity | 30.9% |
| Return on Assets | 19.07% |
| Return on Invested Capital | 25.22% |
| Revenue Per Employee | $1.47M |
| Profits Per Employee | $346.79K |
| Employee Count | 653 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 3.73 |
Taxes
| Income Tax | 31.62M |
| Effective Tax Rate | 12.25% |
Stock Price Statistics
The stock price has increased by -11.81% in the last 52 weeks. The beta is 0.54, so ACADIA Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | -11.81% |
| 50-Day Moving Average | 17.12 |
| 200-Day Moving Average | 16.83 |
| Relative Strength Index (RSI) | 38.91 |
| Average Volume (20 Days) | 1.73M |
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.8M and earned 226.45M in profits. Earnings per share was 1.37.
| Revenue | 957.8M |
| Gross Profit | 875.96M |
| Operating Income | 230.79M |
| Net Income | 226.45M |
| EBITDA | 100.16M |
| EBIT | 84.28M |
| Earnings Per Share (EPS) | 1.37 |
Balance Sheet
The company has 319.59M in cash and 51.99M in debt, giving a net cash position of 267.59M.
| Cash & Cash Equivalents | 319.59M |
| Total Debt | 51.99M |
| Net Cash | 267.59M |
| Retained Earnings | -2.2B |
| Total Assets | 1.19B |
| Working Capital | 543.45M |
Cash Flow
In the last 12 months, operating cash flow was 157.72M and capital expenditures -523K, giving a free cash flow of 157.2M.
| Operating Cash Flow | 157.72M |
| Capital Expenditures | -523K |
| Free Cash Flow | 157.2M |
| FCF Per Share | 0.95 |
Margins
Gross margin is 91.46%, with operating and profit margins of 24.1% and 23.64%.
| Gross Margin | 91.46% |
| Operating Margin | 24.1% |
| Pretax Margin | 26.94% |
| Profit Margin | 23.64% |
| EBITDA Margin | 10.46% |
| EBIT Margin | 24.1% |
| FCF Margin | 16.41% |
Dividends & Yields
ACAD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.45% |
| FCF Yield | 5.17% |
Analyst Forecast
The average price target for ACAD is $23, which is 57.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 57.2% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Scores
| Altman Z-Score | 2.15 |
| Piotroski F-Score | 3 |